Novel manganese-based macrocyclic Magnetic Resonance Imaging (MRI) agent could offer an alternative to gadolinium-based agents Manganese is a trace element naturally occurring in, and efficiently ...
The launch of Pixxoscan expands GE HealthCare’s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers - Clariscan (gadoteric acid) ...
MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...
Ge Healthcare Technologies Inc. (GEHC) announced an update on their ongoing clinical study. The LUMINA trial is a Phase 2/3 study run by GE Healthcare to test a new MRI contrast agent called ...
GE HealthCare Technologies Inc. GEHC has announced a development partnership with Springbok Analytics to combine its MRI technology with Springbok’s AI-powered analysis platform, with the goal of ...
Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin. GE Healthcare, which has its North American headquarters in ...
GE Healthcare is about to release a new MRI that has a wider tube to accommodate obese and claustrophobic patients, according to an article in the Milwaukee Journal Sentinel. Officials at the ...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. GE HealthCare Technologies ...
SIGNA Sprint with Freelium, a new 1.5T sealed magnet MRI system, combines a sustainable design with uncompromised image quality, and operational autonomy to expand access to advanced MR, even in ...
NISKAYUNA — General Electric Co., in partnership with the Department of Defense, is developing a new, more advanced magnetic resonance imaging, or MRI, machine that can better detect mild brain ...
You are at the healthcare provider’s office, and they tell you that you need an MRI scan with contrast dye.
Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...